|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.405 SEK | +3.69% |
|
+3.69% | -64.83% |
| May. 15 | Transcript : Scandion Oncology A/S - Special Call | |
| Mar. 21 | Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival | CI |
Scandion Oncology A/S reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was DKK 76.7 million compared to DKK 51.71 million a year ago. Basic loss per share from continuing operations was DKK 1.87 compared to DKK 1.61 a year ago.
Diluted loss per share from continuing operations was DKK 1.87 compared to DKK 1.61 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -64.83% | 5.34M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
SCANDION ONCOLOGY A/S 
